Skip to main
OSCR
OSCR logo

Oscar Health (OSCR) Stock Forecast & Price Target

Oscar Health (OSCR) Analyst Ratings

Based on 8 analyst ratings
Sell
Strong Buy 0%
Buy 0%
Hold 38%
Sell 50%
Strong Sell 13%

Bulls say

Oscar Health's 2Q25 revenue reached $2.86 billion, showing a strong year-over-year growth of 29%, driven by high retention rates and an increase in special enrollment period (SEP) members, indicating robust demand for its insurance offerings. The company reported a medical loss ratio (MLR) of 91.1%, which, despite being above the consensus estimate, reflects a significant improvement from the previous year's performance and sequentially indicates effective management of healthcare costs relative to premiums. Furthermore, management anticipates increased utilization in 4Q25, suggesting confidence in sustained business momentum and potential for further revenue growth.

Bears say

Oscar Health Inc. reported a significant operating loss of $230.5 million in the second quarter of 2025, which aligns with previous announcements and highlights ongoing financial distress. The company's adjusted EBITDA of negative $199.4 million fell short of market expectations, indicating operational challenges and potential inefficiencies. Additionally, management anticipates a decline in individual membership by year-end, suggesting further erosion of revenue potential and a weakening market position.

Oscar Health (OSCR) has been analyzed by 8 analysts, with a consensus rating of Sell. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 38% suggest Holding, 50% advise Selling, and 13% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oscar Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oscar Health (OSCR) Forecast

Analysts have given Oscar Health (OSCR) a Sell based on their latest research and market trends.

According to 8 analysts, Oscar Health (OSCR) has a Sell consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oscar Health (OSCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.